Price Disclosure Reductions for 2024 April Cycle
The 2024 April cycle has a data collection period of 1 April 2023 to 30 September 2023.
Responsible persons must have disclosed brand data to the Price Disclosure Data Administrator (PDDA) by the deadline of 13 November 2023.
The reduction day is 1 April 2024.
Responsible persons should ensure that their authorised representatives keep their details up to date via the Health Products Portal, and sign up to the PBS Newsletter.
Contents
Outcomes of Price Disclosure calculations
The PDDA calculates weighted average disclosed prices (WADPs) to be provided to the Department of Health and Aged Care. The Minister determines WADPs calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).
The outcomes reflecting these determinations have been published in a legal determination on the Federal Register of Legislation website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their October 2023 PBS approved ex‑manufacturer price and the weighted average disclosed price was below 10% or 30% (as applicable). Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 30 September 2023 will also take the reduction on 1 April 2024 under section 99ADHA of the Act.
Please note an agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes is 11 January 2024.
A list of pharmaceutical items scheduled for a price disclosure reduction and their weighted average disclosed prices is presented in the table below.
| Legal Instrument Drug | Legal Instrument Form | Legal Instrument MoA | Brands of PI designated brands under 99ADHC (Y/N) | Floor Price | Price reduction applied in 2 previous cycles (Y/N?) | Average UPR exceeds 12.5% over 3 cycles (Y/N) | Oct-23 AEMP | Apr-24 AEMP | Percentage difference between Oct-23 and Apr-24 AEMP (%) | UPR threshold (%) | Calculations based on: OWAPD = all brand data GWAPD = originator brand data removed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| adalimumab | Injection 20 mg in 0.4 mL pre-filled syringe | Injection | N | - | - | - | 380.99 | 311.46 | 18.25% | 10% | GWAPD |
| adalimumab | Injection 40 mg in 0.4 mL pre-filled pen | Injection | N | - | - | - | 618.9 | 505.95 | 18.25% | 10% | GWAPD |
| adalimumab | Injection 40 mg in 0.8 mL pre-filled pen | Injection | N | - | - | - | 761.98 | 622.92 | 18.25% | 10% | GWAPD |
| adalimumab | Injection 40 mg in 0.8 mL pre-filled syringe | Injection | N | - | - | - | 761.98 | 622.92 | 18.25% | 10% | GWAPD |
| amiodarone | Tablet containing amiodarone hydrochloride 200 mg | Oral | Y | 5.98 | N | Y | 5.98 | 4.73 | 20.90% | 10% | GWAPD |
| anastrozole | Tablet 1 mg | Oral | Y | 9.24 | N | Y | 9.24 | 7.26 | 21.43% | 10% | GWAPD |
| aprepitant | Capsule 165 mg | Oral | N | - | - | - | 62.3 | 55.17 | 11.44% | 10% | OWAPD |
| aripiprazole | Tablet 10 mg | Oral | Y | 42.28 | N | Y | 42.28 | 28.47 | 32.66% | 30% | GWAPD |
| aripiprazole | Tablet 15 mg | Oral | Y | 60 | N | Y | 60 | 40.4 | 32.67% | 30% | GWAPD |
| aripiprazole | Tablet 20 mg | Oral | Y | 73.04 | N | Y | 73.04 | 49.18 | 32.67% | 30% | GWAPD |
| aripiprazole | Tablet 30 mg | Oral | Y | 89.01 | N | Y | 89.01 | 59.93 | 32.67% | 30% | GWAPD |
| bevacizumab | Solution for I.V. infusion 100 mg in 4 mL | Injection | N | - | - | - | 122 | 90.32 | 25.97% | 10% | OWAPD |
| bevacizumab | Solution for I.V. infusion 400 mg in 16 mL | Injection | N | - | - | - | 488 | 361.27 | 25.97% | 10% | OWAPD |
| bortezomib | Powder for injection 2.5 mg | Injection | N | - | - | - | 187.52 | 55.34 | 70.49% | 10% | OWAPD |
| bortezomib | Powder for injection 3.5 mg | Injection | N | - | - | - | 262.52 | 77.47 | 70.49% | 10% | OWAPD |
| bortezomib | Solution for injection 2.5 mg in 1 mL | Injection | N | - | - | - | 187.52 | 55.34 | 70.49% | 10% | OWAPD |
| bortezomib | Solution for injection 3.5 mg in 1.4 mL | Injection | N | - | - | - | 262.52 | 77.47 | 70.49% | 10% | OWAPD |
| bosentan | Tablet 125 mg (as monohydrate) | Oral | Y | 290.5 | N | Y | 290.5 | 169.3 | 41.72% | 30% | GWAPD |
| bosentan | Tablet 62.5 mg (as monohydrate) | Oral | Y | 290.5 | N | Y | 290.5 | 169.3 | 41.72% | 30% | GWAPD |
| buprenorphine | Transdermal patch 10 mg | Transdermal | N | - | - | - | 15.45 | 12.62 | 18.32% | 10% | GWAPD |
| buprenorphine | Transdermal patch 15 mg | Transdermal | N | - | - | - | 19.64 | 16.04 | 18.33% | 10% | GWAPD |
| buprenorphine | Transdermal patch 20 mg | Transdermal | N | - | - | - | 23.84 | 19.47 | 18.33% | 10% | GWAPD |
| buprenorphine | Transdermal patch 25 mg | Transdermal | N | - | - | - | 27.81 | 22.71 | 18.34% | 10% | GWAPD |
| buprenorphine | Transdermal patch 30 mg | Transdermal | N | - | - | - | 31.78 | 25.95 | 18.34% | 10% | GWAPD |
| buprenorphine | Transdermal patch 40 mg | Transdermal | N | - | - | - | 39.73 | 32.45 | 18.32% | 10% | GWAPD |
| buprenorphine | Transdermal patch 5 mg | Transdermal | N | - | - | - | 8.58 | 7.01 | 18.30% | 10% | GWAPD |
| cabazitaxel | Concentrated injection 60 mg in 1.5 mL, with diluent | Injection | N | - | - | - | 178.77 | 88.67 | 50.40% | 10% | OWAPD |
| cabazitaxel | Solution concentrate for I.V. infusion 60 mg in 3 mL | Injection | N | - | - | - | 152.53 | 88.67 | 41.87% | 10% | OWAPD |
| cabazitaxel | Solution concentrate for I.V. infusion 60 mg in 6 mL | Injection | N | - | - | - | 152.53 | 88.67 | 41.87% | 10% | OWAPD |
| ciclosporin | Capsule 100 mg | Oral | Y | 122.35 | N | Y | 122.35 | 93.45 | 23.62% | 10% | GWAPD |
| ciclosporin | Capsule 25 mg | Oral | Y | 28.86 | N | Y | 28.86 | 22.04 | 23.63% | 10% | GWAPD |
| ciclosporin | Capsule 50 mg | Oral | Y | 60.05 | N | Y | 60.05 | 45.87 | 23.61% | 10% | GWAPD |
| cinacalcet | Tablet 30 mg (as hydrochloride) | Oral | N | - | - | - | 27.95 | 23.72 | 15.13% | 10% | OWAPD |
| cinacalcet | Tablet 60 mg (as hydrochloride) | Oral | N | - | - | - | 55.91 | 47.44 | 15.15% | 10% | OWAPD |
| cinacalcet | Tablet 90 mg (as hydrochloride) | Oral | N | - | - | - | 83.86 | 71.16 | 15.14% | 10% | OWAPD |
| clindamycin | Capsule 150 mg (as hydrochloride) | Oral | Y | 5.15 | N | Y | 5.15 | 4.17 | 19.03% | 10% | GWAPD |
| dasatinib | Tablet 100 mg | Oral | N | - | - | - | 2050.27 | 1770.45 | 13.65% | 10% | OWAPD |
| dasatinib | Tablet 20 mg | Oral | N | - | - | - | 1244.78 | 1074.89 | 13.65% | 10% | OWAPD |
| dasatinib | Tablet 50 mg | Oral | N | - | - | - | 2050.27 | 1770.45 | 13.65% | 10% | OWAPD |
| dasatinib | Tablet 70 mg | Oral | N | - | - | - | 2538.37 | 2191.93 | 13.65% | 10% | OWAPD |
| deferasirox | Tablet 180 mg | Oral | N | - | - | - | 92.85 | 60.54 | 34.80% | 10% | OWAPD |
| deferasirox | Tablet 360 mg | Oral | N | - | - | - | 185.69 | 121.09 | 34.79% | 10% | OWAPD |
| deferasirox | Tablet 90 mg | Oral | N | - | - | - | 46.43 | 30.27 | 34.81% | 10% | OWAPD |
| dimethyl fumarate | Capsule (modified release) 120 mg | Oral | N | - | - | - | 173.59 | 154.25 | 11.14% | 10% | OWAPD |
| donepezil | Tablet containing donepezil hydrochloride 10 mg | Oral | Y | 7.44 | N | Y | 7.44 | 5.46 | 26.61% | 10% | GWAPD |
| donepezil | Tablet containing donepezil hydrochloride 5 mg | Oral | Y | 7.44 | N | Y | 7.44 | 5.46 | 26.61% | 10% | GWAPD |
| dorzolamide | Eye drops 20 mg (as hydrochloride) per mL, 5 mL | Application to the eye | Y | 6.25 | N | Y | 6.25 | 4.93 | 21.12% | 10% | GWAPD |
| duloxetine | Capsule 60 mg (as hydrochloride) | Oral | Y | 4.38 | N | Y | 4.38 | 4 | 25.11% | 10% | GWAPD |
| entecavir | Tablet 0.5 mg (as monohydrate) | Oral | Y | 45.78 | N | Y | 45.78 | 34.14 | 25.43% | 10% | OWAPD |
| entecavir | Tablet 1 mg (as monohydrate) | Oral | Y | 74.44 | N | Y | 74.44 | 55.52 | 25.42% | 10% | OWAPD |
| erlotinib | Tablet 100 mg (as hydrochloride) | Oral | N | - | - | - | 531.47 | 460.68 | 13.32% | 10% | OWAPD |
| erlotinib | Tablet 150 mg (as hydrochloride) | Oral | N | - | - | - | 657.49 | 569.91 | 13.32% | 10% | OWAPD |
| erlotinib | Tablet 25 mg (as hydrochloride) | Oral | N | - | - | - | 146.43 | 126.93 | 13.32% | 10% | OWAPD |
| ezetimibe with simvastatin | Tablet 10 mg-10 mg | Oral | Y | 9.32 | N | Y | 9.32 | 7.76 | 16.74% | 10% | GWAPD |
| ezetimibe with simvastatin | Tablet 10 mg-20 mg | Oral | Y | 9.79 | N | Y | 9.79 | 8.15 | 16.75% | 10% | GWAPD |
| ezetimibe with simvastatin | Tablet 10 mg-40 mg | Oral | Y | 10.45 | N | Y | 10.45 | 8.7 | 16.75% | 10% | GWAPD |
| ezetimibe with simvastatin | Tablet 10 mg-80 mg | Oral | Y | 11.38 | N | Y | 11.38 | 9.47 | 16.78% | 10% | GWAPD |
| fentanyl | Transdermal patch 1.28 mg | Transdermal | Y | 6.37 | N | Y | 6.37 | 4.81 | 24.49% | 10% | GWAPD |
| fentanyl | Transdermal patch 10.20 mg | Transdermal | Y | 25.31 | N | Y | 25.31 | 19.11 | 24.50% | 10% | GWAPD |
| fentanyl | Transdermal patch 12.375 mg | Transdermal | Y | 25.21 | N | Y | 25.21 | 19.04 | 24.47% | 10% | GWAPD |
| fentanyl | Transdermal patch 12.6 mg | Transdermal | Y | 20.4 | N | Y | 20.4 | 15.4 | 24.51% | 10% | GWAPD |
| fentanyl | Transdermal patch 16.8 mg | Transdermal | Y | 25.31 | N | Y | 25.31 | 19.11 | 24.50% | 10% | GWAPD |
| fentanyl | Transdermal patch 2.063 mg | Transdermal | Y | 7.87 | N | Y | 7.87 | 5.94 | 24.52% | 10% | GWAPD |
| fentanyl | Transdermal patch 2.1 mg | Transdermal | Y | 6.37 | N | Y | 6.37 | 4.81 | 24.49% | 10% | GWAPD |
| fentanyl | Transdermal patch 2.55 mg | Transdermal | Y | 8.1 | N | Y | 8.1 | 6.12 | 24.44% | 10% | GWAPD |
| fentanyl | Transdermal patch 4.125 mg | Transdermal | Y | 10.01 | N | Y | 10.01 | 7.56 | 24.48% | 10% | GWAPD |
| fentanyl | Transdermal patch 4.2 mg | Transdermal | Y | 8.1 | N | Y | 8.1 | 6.12 | 24.44% | 10% | GWAPD |
| fentanyl | Transdermal patch 5.10 mg | Transdermal | Y | 14.89 | N | Y | 14.89 | 11.24 | 24.51% | 10% | GWAPD |
| fentanyl | Transdermal patch 7.65 mg | Transdermal | Y | 20.4 | N | Y | 20.4 | 15.4 | 24.51% | 10% | GWAPD |
| fentanyl | Transdermal patch 8.25 mg | Transdermal | Y | 18.4 | N | Y | 18.4 | 13.89 | 24.51% | 10% | GWAPD |
| fentanyl | Transdermal patch 8.4 mg | Transdermal | Y | 14.89 | N | Y | 14.89 | 11.24 | 24.51% | 10% | GWAPD |
| fluconazole | Capsule 100 mg | Oral | Y | 15.47 | N | Y | 15.47 | 11.53 | 25.47% | 10% | GWAPD |
| fluconazole | Capsule 200 mg | Oral | Y | 30.14 | N | Y | 30.14 | 22.47 | 25.45% | 10% | GWAPD |
| fluconazole | Capsule 50 mg | Oral | Y | 7.95 | N | Y | 7.95 | 5.93 | 25.41% | 10% | GWAPD |
| fluorouracil | Injection 2500 mg in 50 mL | Injection | Y | 12.11 | N | Y | 12.11 | 9.96 | 17.75% | 10% | OWAPD |
| fluorouracil | Injection 5000 mg in 100 mL | Injection | Y | 24.22 | N | Y | 24.22 | 19.92 | 17.75% | 10% | OWAPD |
| gliclazide | Tablet 30 mg (modified release) | Oral | N | - | - | - | 5.61 | 4.91 | 12.48% | 10% | GWAPD |
| gliclazide | Tablet 60 mg (modified release) | Oral | N | - | - | - | 4.48 | 3.92 | 12.50% | 10% | GWAPD |
| gliclazide | Tablet 80 mg | Oral | N | - | - | - | 5.45 | 4.77 | 12.48% | 10% | GWAPD |
| hydromorphone | Injection containing hydromorphone hydrochloride 10 mg in 1 mL | Injection | N | - | - | - | 8.81 | 7.52 | 14.64% | 10% | GWAPD |
| hydromorphone | Injection containing hydromorphone hydrochloride 2 mg in 1 mL | Injection | N | - | - | - | 6.6 | 5.64 | 14.55% | 10% | GWAPD |
| imatinib | Capsule 100 mg (as mesilate) | Oral | Y | 209.62 | Y | Y | 209.62 | 124.56 | 40.58% | 30% | GWAPD |
| imatinib | Capsule 400 mg (as mesilate) | Oral | Y | 419.23 | Y | Y | 419.23 | 249.11 | 40.58% | 30% | GWAPD |
| imatinib | Tablet 100 mg (as mesilate) | Oral | Y | 209.62 | Y | Y | 209.62 | 124.56 | 40.58% | 30% | GWAPD |
| imatinib | Tablet 400 mg (as mesilate) | Oral | Y | 419.23 | Y | Y | 419.23 | 249.11 | 40.58% | 30% | GWAPD |
| indapamide | Tablet containing indapamide hemihydrate 2.5 mg | Oral | Y | 4.91 | N | Y | 4.91 | 4.14 | 15.68% | 10% | GWAPD |
| infliximab | Powder for I.V. infusion 100 mg | Injection | Y | 253.52 | N | Y | 253.52 | 186.16 | 26.57% | 10% | GWAPD |
| lamotrigine | Tablet 100 mg | Oral | Y | 11.79 | N | Y | 11.79 | 9.13 | 22.56% | 10% | GWAPD |
| lamotrigine | Tablet 200 mg | Oral | Y | 19.82 | N | Y | 19.82 | 15.35 | 22.55% | 10% | GWAPD |
| lamotrigine | Tablet 25 mg | Oral | Y | 4.25 | N | Y | 4.25 | 4 | 22.59% | 10% | GWAPD |
| lamotrigine | Tablet 50 mg | Oral | Y | 7.08 | N | Y | 7.08 | 5.48 | 22.60% | 10% | GWAPD |
| latanoprost | Eye drops 50 micrograms per mL, 2.5 mL | Application to the eye | Y | 4.14 | N | Y | 4.14 | 4 | 29.71% | 10% | GWAPD |
| leflunomide | Tablet 10 mg | Oral | Y | 15.3 | N | Y | 15.3 | 11.88 | 22.35% | 10% | GWAPD |
| leflunomide | Tablet 20 mg | Oral | Y | 23.3 | N | Y | 23.3 | 18.09 | 22.36% | 10% | GWAPD |
| lenalidomide | Capsule 10 mg | Oral | N | - | - | - | 1014.2 | 886.72 | 12.57% | 10% | OWAPD |
| lenalidomide | Capsule 15 mg | Oral | N | - | - | - | 1221.5 | 1067.96 | 12.57% | 10% | OWAPD |
| lenalidomide | Capsule 25 mg | Oral | N | - | - | - | 1598.14 | 1397.25 | 12.57% | 10% | OWAPD |
| lenalidomide | Capsule 5 mg | Oral | N | - | - | - | 774.17 | 676.86 | 12.57% | 10% | OWAPD |
| letrozole | Tablet 2.5 mg | Oral | Y | 13.88 | N | Y | 13.88 | 9.72 | 29.97% | 10% | GWAPD |
| levodopa with carbidopa and entacapone | Tablet 100 mg-25 mg (as monohydrate)-200 mg | Oral | N | - | - | - | 84.34 | 67.44 | 20.04% | 10% | GWAPD |
| levodopa with carbidopa and entacapone | Tablet 125 mg-31.25 mg (as monohydrate)-200 mg | Oral | N | - | - | - | 87.54 | 70 | 20.04% | 10% | GWAPD |
| levodopa with carbidopa and entacapone | Tablet 150 mg-37.5 mg (as monohydrate)-200 mg | Oral | N | - | - | - | 92.32 | 73.82 | 20.04% | 10% | GWAPD |
| levodopa with carbidopa and entacapone | Tablet 200 mg-50 mg (as monohydrate)-200 mg | Oral | N | - | - | - | 99.66 | 79.69 | 20.04% | 10% | GWAPD |
| levodopa with carbidopa and entacapone | Tablet 50 mg-12.5 mg (as monohydrate)-200 mg | Oral | N | - | - | - | 76.36 | 61.06 | 20.04% | 10% | GWAPD |
| levodopa with carbidopa and entacapone | Tablet 75 mg-18.75 mg (as monohydrate)-200 mg | Oral | N | - | - | - | 79.87 | 63.86 | 20.05% | 10% | GWAPD |
| levonorgestrel with ethinylestradiol | Pack containing 21 tablets 150 micrograms-30 micrograms and 7 inert tablets | Oral | Y | 4.75 | N | Y | 4.75 | 4 | 19.58% | 10% | GWAPD |
| lurasidone | Tablet containing lurasidone hydrochloride 40 mg | Oral | N | - | - | - | 27.48 | 18.99 | 30.90% | 10% | GWAPD |
| lurasidone | Tablet containing lurasidone hydrochloride 80 mg | Oral | N | - | - | - | 54.96 | 37.97 | 30.91% | 10% | GWAPD |
| metformin | Tablet (extended release) containing metformin hydrochloride 1 g | Oral | Y | 4.01 | N | Y | 4.01 | 4 | 14.96% | 10% | GWAPD |
| metformin | Tablet (extended release) containing metformin hydrochloride 500 mg | Oral | Y | 4.01 | N | Y | 4.01 | 4 | 14.96% | 10% | GWAPD |
| metformin | Tablet containing metformin hydrochloride 1 g | Oral | Y | 4.36 | N | Y | 4.36 | 4 | 14.91% | 10% | GWAPD |
| metoprolol succinate | Tablet 190 mg (controlled release) | Oral | Y | 33.83 | N | Y | 33.83 | 26.47 | 21.76% | 10% | GWAPD |
| metoprolol succinate | Tablet 23.75 mg (controlled release) | Oral | Y | 4.59 | N | Y | 4.59 | 4 | 21.79% | 10% | GWAPD |
| metoprolol succinate | Tablet 47.5 mg (controlled release) | Oral | Y | 21.66 | N | Y | 21.66 | 16.94 | 21.79% | 10% | GWAPD |
| metoprolol succinate | Tablet 95 mg (controlled release) | Oral | Y | 27.06 | N | Y | 27.06 | 21.17 | 21.77% | 10% | GWAPD |
| moclobemide | Tablet 150 mg | Oral | Y | 7.79 | N | Y | 7.79 | 6.14 | 21.18% | 10% | GWAPD |
| moclobemide | Tablet 300 mg | Oral | Y | 13 | N | Y | 13 | 10.24 | 21.23% | 10% | GWAPD |
| modafinil | Tablet 100 mg | Oral | Y | 72.13 | N | Y | 72.13 | 55.6 | 22.92% | 10% | GWAPD |
| montelukast | Tablet, chewable, 4 mg (as sodium) | Oral | Y | 5.49 | N | Y | 5.49 | 4.09 | 25.50% | 10% | OWAPD |
| montelukast | Tablet, chewable, 5 mg (as sodium) | Oral | Y | 5.17 | N | Y | 5.17 | 4 | 25.53% | 10% | OWAPD |
| mycophenolic acid | Capsule containing mycophenolate mofetil 250 mg | Oral | Y | 16.38 | N | Y | 16.38 | 12.74 | 22.22% | 10% | GWAPD |
| mycophenolic acid | Tablet containing mycophenolate mofetil 500 mg | Oral | Y | 32.74 | N | Y | 32.74 | 25.46 | 22.24% | 10% | GWAPD |
| nebivolol | Tablet 1.25 mg (as hydrochloride) | Oral | N | - | - | - | 11.76 | 9.78 | 16.84% | 10% | GWAPD |
| nebivolol | Tablet 10 mg (as hydrochloride) | Oral | N | - | - | - | 33.19 | 27.6 | 16.84% | 10% | GWAPD |
| nebivolol | Tablet 5 mg (as hydrochloride) | Oral | N | - | - | - | 29.37 | 24.42 | 16.85% | 10% | GWAPD |
| nicorandil | Tablets 10 mg, 60 | Oral | Y | 9.51 | N | Y | 9.51 | 8.07 | 15.14% | 10% | GWAPD |
| nicorandil | Tablets 20 mg, 60 | Oral | Y | 13.25 | N | Y | 13.25 | 11.24 | 15.17% | 10% | GWAPD |
| olmesartan | Tablet containing olmesartan medoxomil 40 mg | Oral | Y | 6.95 | N | Y | 6.95 | 5.67 | 18.42% | 10% | GWAPD |
| olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg | Oral | Y | 8.04 | N | Y | 8.04 | 6.2 | 22.89% | 10% | GWAPD |
| olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg | Oral | Y | 7.11 | N | Y | 7.11 | 5.49 | 22.78% | 10% | GWAPD |
| palonosetron | Injection 250 micrograms (as hydrochloride) in 5 mL | Injection | N | - | - | - | 22.04 | 9.91 | 55.04% | 10% | OWAPD |
| paraffin | Eye drops containing liquid paraffin, glycerol, tyloxapol, poloxamer-188, trometamol hydrochloride, trometamol, cetalkonium chloride, 10 mL (preservative free) | Application to the eye | N | - | - | - | 23.8 | 20.78 | 12.69% | 10% | OWAPD |
| paraffin | Eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g | Application to the eye | N | - | - | - | 4.1 | 3.58 | 12.68% | 10% | OWAPD |
| paraffin | Pack containing 2 tubes eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g | Application to the eye | N | - | - | - | 7.86 | 6.86 | 12.72% | 10% | OWAPD |
| riluzole | Tablet 50 mg | Oral | Y | 148.07 | N | Y | 148.07 | 113.3 | 23.48% | 10% | GWAPD |
| risperidone | Tablet 1 mg | Oral | Y | 4.7 | N | Y | 4.7 | 4 | 17.23% | 10% | GWAPD |
| risperidone | Tablet 2 mg | Oral | Y | 10.74 | N | Y | 10.74 | 8.9 | 17.13% | 10% | GWAPD |
| risperidone | Tablet 3 mg | Oral | Y | 16.57 | N | Y | 16.57 | 13.73 | 17.14% | 10% | GWAPD |
| risperidone | Tablet 4 mg | Oral | Y | 22.36 | N | Y | 22.36 | 18.52 | 17.17% | 10% | GWAPD |
| sitagliptin | Tablet 100 mg | Oral | N | - | - | - | 28.43 | 22.93 | 19.35% | 10% | OWAPD |
| sitagliptin | Tablet 25 mg | Oral | N | - | - | - | 28.43 | 22.93 | 19.35% | 10% | OWAPD |
| sitagliptin | Tablet 50 mg | Oral | N | - | - | - | 28.43 | 22.93 | 19.35% | 10% | OWAPD |
| sunitinib | Capsule 12.5 mg | Oral | N | - | - | - | 707.27 | 581.73 | 17.75% | 10% | OWAPD |
| sunitinib | Capsule 25 mg | Oral | N | - | - | - | 1423.46 | 1170.8 | 17.75% | 10% | OWAPD |
| sunitinib | Capsule 37.5 mg | Oral | N | - | - | - | 2133.39 | 1754.71 | 17.75% | 10% | OWAPD |
| sunitinib | Capsule 50 mg | Oral | N | - | - | - | 2882.07 | 2370.5 | 17.75% | 10% | OWAPD |
| tacrolimus | Capsule 0.75 mg | Oral | Y | 147.64 | Y | Y | 147.64 | 98.08 | 33.57% | 30% | GWAPD |
| tamoxifen | Tablet 20 mg (as citrate) | Oral | Y | 6.27 | N | Y | 6.27 | 4.97 | 20.73% | 10% | GWAPD |
| temozolomide | Capsule 100 mg | Oral | Y | 81.63 | N | Y | 81.63 | 59.7 | 26.87% | 10% | GWAPD |
| temozolomide | Capsule 140 mg | Oral | Y | 112.58 | N | Y | 112.58 | 82.33 | 26.87% | 10% | GWAPD |
| temozolomide | Capsule 180 mg | Oral | Y | 136.33 | N | Y | 136.33 | 99.7 | 26.87% | 10% | GWAPD |
| temozolomide | Capsule 20 mg | Oral | Y | 19.05 | N | Y | 19.05 | 13.93 | 26.88% | 10% | GWAPD |
| temozolomide | Capsule 250 mg | Oral | Y | 193.95 | N | Y | 193.95 | 141.84 | 26.87% | 10% | GWAPD |
| temozolomide | Capsule 5 mg | Oral | Y | 6.48 | N | Y | 6.48 | 4.74 | 26.85% | 10% | GWAPD |
| tenofovir with emtricitabine | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | Oral | Y | 23.4 | N | Y | 23.4 | 16.55 | 29.27% | 10% | OWAPD |
| tenofovir with emtricitabine | Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg | Oral | Y | 23.4 | N | Y | 23.4 | 16.55 | 29.27% | 10% | OWAPD |
| tenofovir with emtricitabine | Tablet containing tenofovir disoproxil phosphate 291 mg with emtricitabine 200 mg | Oral | Y | 23.4 | N | Y | 23.4 | 16.55 | 29.27% | 10% | OWAPD |
| tenofovir with emtricitabine | Tablet containing tenofovir disoproxil succinate 301 mg with emtricitabine 200 mg | Oral | Y | 23.4 | N | Y | 23.4 | 16.55 | 29.27% | 10% | OWAPD |
| topiramate | Tablet 100 mg | Oral | Y | 12.6 | N | Y | 12.6 | 9.72 | 22.86% | 10% | GWAPD |
| topiramate | Tablet 200 mg | Oral | Y | 21.17 | N | Y | 21.17 | 16.34 | 22.82% | 10% | GWAPD |
| topiramate | Tablet 25 mg | Oral | Y | 4.88 | N | Y | 4.88 | 4 | 22.75% | 10% | GWAPD |
| topiramate | Tablet 50 mg | Oral | Y | 8.01 | N | Y | 8.01 | 6.18 | 22.85% | 10% | GWAPD |
| valproic acid | Tablet (enteric coated) containing sodium valproate 200 mg | Oral | Y | 4.63 | N | Y | 4.63 | 4 | 18.57% | 10% | GWAPD |
| valproic acid | Tablet (enteric coated) containing sodium valproate 500 mg | Oral | Y | 9.17 | N | Y | 9.17 | 7.47 | 18.54% | 10% | GWAPD |
| vancomycin | Capsule 125 mg (125,000 I.U.) (as hydrochloride) | Oral | N | - | - | - | 66.21 | 50.69 | 23.44% | 10% | GWAPD |
| vancomycin | Capsule 250 mg (250,000 I.U.) (as hydrochloride) | Oral | N | - | - | - | 132.39 | 101.36 | 23.44% | 10% | GWAPD |
| zoledronic acid | Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL | Injection | Y | 70 | N | Y | 70 | 59.56 | 14.91% | 10% | GWAPD |
| zoledronic acid | Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL | Injection | Y | 67.26 | N | Y | 67.26 | 57.23 | 14.91% | 10% | GWAPD |
A list of brands of pharmaceutical items that will be subject to an automatic flow-on price disclosure reduction under section 99ADHB of the National Health Act 1953 on 1 April 2024 is available in the 2024 April Combination Flow-on Reductions from Price Disclosure Summary (Excel 13 KB). Sponsors were able to apply for Ministerial discretion for these reductions to be reduced or not apply. For more information see Ministerial Discretion.
Indicative prices of brands scheduled for a price disclosure reduction
The dispensed prices for brands scheduled for price disclosure reductions in this cycle will be published to assist responsible persons and other stakeholders.
Indicative prices are not published for any medicines that are:
- not taking a price disclosure reduction in this cycle;
- new brands after the date of publication;
- brands with other price changes on the reduction day.
The indicative prices reports have been replaced by the confirmed prices reports below.
Confirmed prices of brands scheduled for a price disclosure reduction
This report sets out the dispensed prices of brands scheduled for a price disclosure reduction.
The confirmed prices reports for the 2024 April cycle can be downloaded below:
Brand price reductions and savings to patients
This report sets out price reductions per brand and potential individual savings to non-concessional patients from 1 April 2024. This information is made available to assist patients with understanding how much they may save on their PBS medicines.
The report does not include any brands of medicines that have other price changes, or brands that are new to the PBS on the reduction day.
The brand price reductions report for the 2024 April cycle can be downloaded below.
Last updated
28 March 2024